Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 4:46 AM
Ignite Modification Date:
2025-12-25 @ 4:46 AM
NCT ID:
NCT04071418
Eligibility Criteria:
Inclusion Criteria:
* (1) Age 18-75 years old
* (2) Pathological diagnosis of NSCLC, recurrence after radiotherapy, lesion diameter less than 5 cm
* (3) No systemic metastasis or metastasis, metastasis has been controlled by pre-treatment
* (4) No bleeding tendency, anticoagulant therapy and/or anti-platelet coagulant drugs should be stopped for at least one week before seed implantation
* (5) No serious or uncontrolled underlying diseases (such as severe or uncontrolled high). Blood pressure, diabetes mellitus, cardiovascular and cerebrovascular diseases and organ dysfunction, etc.
* (6) There is a suitable puncture path, which is expected to achieve the therapeutic dose
* (7) KPS \> 70 points, which is expected to be able to tolerate puncture/RISI therapy, and the expected survival time is longer than 3 months.
Exclusion Criteria:
* (1) Poor basic pulmonary function with severe emphysema, bullae and interstitial pneumonia
* (2) Liquefaction and necrosis in a large area near the mediastinum or focus, with high risk of puncture bleeding or poor seeds distribution
* (3) Infection and ulcer in puncture site
* (4) Pregnant women, lactating women, children and psychiatric patients
* (5) Patients who are participating in other clinical studies
* (6) Poor compliance, unable to complete the treatment
* (7) The researchers think that it is not appropriate to participate in this clinical trial
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Maximum Age:
75 Years
Study:
NCT04071418
Study Brief:
Protocol Section:
NCT04071418